# SUCLA2 siRNA (m): sc-76599



The Power to Question

# **BACKGROUND**

SUCLA2 (succinate-CoA ligase, ADP-forming,  $\beta$  subunit), also known as A-BETA, SCS- $\beta$ A or renal carcinoma antigen NY-REN-39, is a 463 amino acid mitochondrial matrix enzyme that belongs to the succinate/malate CoA ligase  $\beta$  subunit family. Widely expressed, SUCLA2 dimerizes with the SCS  $\alpha$  subunit to form SCS-A, an essential component of the tricarboxylic acid cycle. Defects in SUCLA2 may be involved in a group of autosomal recessive disorders known as Mitochondrial DNA depletion syndromes (MDSs) that are characterized by a decrease in mitochondrial DNA copy numbers in affected tissues. Progressive external ophthalmoplegia (PEO), ataxia-neuropathy and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) may also be associated with mutations in SUCLA2. Two isoforms of SUCLA2 exists due to alternative splicing events.

# **REFERENCES**

- Furuyama, K., et al. 2000. Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. J. Clin. Invest. 105: 757-764.
- Elpeleg, O., et al. 2005. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am. J. Hum. Genet. 76: 1081-1086.
- 3. Ostergaard, E., et al. 2007. Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. Brain 130: 853-861
- Carrozzo, R., et al. 2007. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain 130: 862-874.
- Bourdon, A., et al. 2007. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 39: 776-780.
- Copeland, W.C. 2008. Inherited mitochondrial diseases of DNA replication. Annu. Rev. Med. 59: 131-146.

# CHROMOSOMAL LOCATION

Genetic locus: Sucla2 (mouse) mapping to 14 D3.

#### **PRODUCT**

SUCLA2 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu\text{M}$  solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see SUCLA2 shRNA Plasmid (m): sc-76599-SH and SUCLA2 shRNA (m) Lentiviral Particles: sc-76599-V as alternate gene silencing products.

For independent verification of SUCLA2 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-76599A, sc-76599B and sc-76599C.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

# **APPLICATIONS**

SUCLA2 siRNA (m) is recommended for the inhibition of SUCLA2 expression in mouse cells.

#### **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

# **GENE EXPRESSION MONITORING**

SUCLA2 (A-9): sc-374107 is recommended as a control antibody for monitoring of SUCLA2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

# **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor SUCLA2 gene expression knockdown using RT-PCR Primer: SUCLA2 (m)-PR: sc-76599-PR (20  $\mu$ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

**Santa Cruz Biotechnology, Inc.** 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**